Vascepa Brand Price vs. Generic Entry
Vascepa (icosapent ethyl), made by Amarin, treats high triglycerides. The brand 0.5g capsule costs $300-$400 for a 30-day supply (120 capsules) without insurance, or $10-$15 copay with coverage.[1] Generic versions launched in March 2024 from Dr. Reddy's and Hikma, priced at $20-$50 per month— an 85-95% drop.[2][3]
How Much Savings Per Prescription
Patients switching save $250-$350 monthly at retail prices. Annual savings hit $3,000-$4,200 per patient. With insurance, out-of-pocket drops from $100-$200/year to under $20.[4] Exact savings vary by pharmacy, dose (2-4g daily), and insurer negotiations.
When Generics Became Available
FDA approved generics March 25, 2024, after Amarin lost patent disputes. Multiple ANDAs cleared, including from Cipla and MSN Labs by late 2024. Supply ramped up quickly, with 90% of prescriptions generic by Q3 2024.[5]
Impact on Overall U.S. Spending
Vascepa peaked at $1.1 billion annual sales in 2021. Generics cut payer costs by $800 million+ yearly, per IQVIA data, as 70%+ of scripts shifted generic within months.[6] Medicare Part D alone saves $200-$300 million annually.
Factors Affecting Your Savings
- Insurance: Commercial plans cover generics at Tier 1 ($5-$10 copay); Medicare at $0-$20 after deductible.[7]
- Pharmacy: Walmart or Costco offer generics at $25/month cash; GoodRx coupons drop to $15.[8]
- Dose/Supply: 4g daily (8 capsules) doubles costs but still saves $500+/month vs. brand.
- Regional Variation: Prices 10-20% higher in rural areas.
Patent Status and Future Competition
Amarin's key patents expired 2023-2024 amid challenges; no major exclusivity left. DrugPatentWatch lists 15+ generic approvals, with more entering 2025, potentially pushing prices under $10/month.[9] No biosimilar needed—it's a small molecule.
[1] GoodRx.com, Vascepa pricing (accessed Oct 2024).
[2] FDA Orange Book, ANDA approvals for icosapent ethyl.
[3] Dr. Reddy's press release, Mar 26, 2024.
[4] IQVIA National Prescription Audit, Q2-Q3 2024.
[5] Amarin Q2 2024 earnings call.
[6] FiercePharma, Vascepa generic impact analysis (Aug 2024).
[7] CMS Medicare Part D formulary data.
[8] GoodRx.com generic icosapent ethyl coupons.
[9] DrugPatentWatch.com (icosapent ethyl patents and generics).